Staging and prognostic factor evaluation in soft tissue sarcoma.
Staging and prognostic factor evaluation in soft tissue sarcoma.
复制标题
DOI：
10.1016/s1055-3207(03)00011-5
复制
发表时间：
2003-04-01
影响因子：
1.9
通讯作者：
Pisters, Peter W
中科院分区：
文献类型：
--
作者：
O'Sullivan, Brian;Pisters, Peter W
在过去的十年中，STS的临床病理预后因素的阐明受到了极大的重视。这使得在表现时能够识别“高危”患者。分子因素可能会进一步完善高危患者的识别。与环境相关的预后因素往往容易改变，所有STS患者在治疗前可能都应该进行专科咨询，以便他们能够从最佳的诊断、治疗和多学科方法中受益。对预后问题的持续追求也应该认识到患者疾病预后过程的动态性质。
Over the past decade, there has been significant emphasis on the elucidation of clinicopathologic prognostic factors in STS. This has allowed for identification of the "high-risk" patient at presentation. Molecular factors may further refine the identification of high-risk patients. Setting-related prognostic factors are often amenable to change, and all STS patients should probably be referred for specialty consultation before treatment so that they can benefit from optimal diagnostic, therapeutic, and multidisciplinary approaches. The ongoing pursuit of prognostic issues should also recognize the dynamic nature of prognosis course in a patient's disease.